The KDCA (Chief Jeong Eun-kyeong) announced that it had decided at a Cabinet meeting on the 14th to ₩299.2 billion as a reserve for additional purchases of COVID-19 treatments.

It is equivalent to ₩192 billion for oral treatment of COVID-19, ₩107.2 billion for antiviral drugs (Remdesivir) and antibody therapy (Regkirona), which are existing tx. It is aimed at pre-purchasing oral treatments and purchasing additional existing treatments as the number of confirmed patients continues to increase to 7,000 recently.

Currently, the COVID-19 oral treatment has completed a pre-purchase contract for 3.12 million people (242 million people for MSD and 70,000 people for Pfizer) with